Q32 Bio Inc
NASDAQ: QTTB · HEALTHCARE · BIOTECHNOLOGY
Updated 2026-06-04
Q32 Bio Inc (QTTB) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $5.32M | $1.67M | $2.70M | $33.97M | $6.65M | $-6.65M | $0.00 | $53.74M |
| Revenue growth (YoY) | — | — | — | -68.7% | +62.2% | +1157.3% | -80.4% | -200.0% | +100.0% | — |
| Cost of revenue | $239797.00 | $684214.00 | — | — | — | $9.54M | $2.60M | $499000.00 | $487000.00 | $391000.00 |
| Gross profit | $-239797.00 | $-684214.00 | $5.32M | $1.67M | $2.70M | $24.43M | $6.65M | $-6.65M | $-487000.00 | $53.35M |
| Gross margin | — | — | 100.0% | 100.0% | 100.0% | 71.9% | 100.0% | 100.0% | — | 99.3% |
| R&D | $5.69M | $21.38M | $47.95M | $89.40M | $100.39M | $93.08M | $35.81M | $31.73M | $48.14M | $19.16M |
| SG&A | — | — | — | — | — | $6.76M | $10.06M | $9.88M | $17.96M | $17.68M |
| Operating income | $-10.00M | $-29.66M | $-59.93M | $-109.94M | $-130.26M | $-95.95M | $-39.23M | $-48.26M | $-66.10M | $16.90M |
| Operating margin | — | — | -1126.0% | -6599.2% | -4821.0% | -282.4% | -589.8% | 725.5% | — | 31.5% |
| EBITDA | $-7.81M | $-29.31M | $-58.64M | $-97.60M | $-119.79M | $-86.22M | $-38.85M | $-47.76M | $-45.30M | $17.29M |
| EBITDA margin | — | — | -1101.8% | -5858.2% | -4433.4% | -253.8% | -584.2% | 718.0% | — | 32.2% |
| EBIT | $-8.05M | $-29.99M | $-59.93M | $-103.92M | $-128.69M | $-95.76M | $-39.23M | $-48.26M | $-45.79M | $16.90M |
| Interest expense | — | — | — | — | — | — | — | — | $300000.00 | $1.10M |
| Income tax | $2.00 | $-4.00 | — | — | $-1.00 | $547000.00 | $62000.00 | $318000.00 | $21000.00 | — |
| Effective tax rate | -0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -0.6% | -0.1% | -0.6% | -0.0% | 0.0% |
| Net income | $-8.05M | $-29.99M | $-55.58M | $-103.92M | $-128.69M | $-95.76M | $-42.81M | $-53.74M | $-47.73M | $29.82M |
| Net income growth (YoY) | — | -272.7% | -85.3% | -87.0% | -23.8% | +25.6% | +55.3% | -25.5% | +11.2% | +162.5% |
| Profit margin | — | — | -1044.3% | -6237.5% | -4762.9% | -281.9% | -643.6% | 808.0% | — | 55.5% |
Frequently asked questions
What is Q32 Bio Inc's revenue?
Q32 Bio Inc's trailing twelve-month revenue is $53.74M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How profitable is QTTB?
In its most recent fiscal year, QTTB ran a gross margin of 99.27%, an operating margin of 31.45%, and a net margin of 55.49%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.
How much free cash flow does QTTB generate?
QTTB produced $-33.55M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is QTTB's balance sheet healthy?
QTTB holds $48.30M in cash and equivalents against $3.47M in long-term debt, on $42.01M of shareholder equity. Cash on hand exceeds long-term debt, so the balance sheet adds little financial risk to the thesis.